Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Department of Clinical Neuroimmunology and Neurochemistry, Hannover Medical School, Hannover, Germany.
Sci Rep. 2021 Apr 19;11(1):8527. doi: 10.1038/s41598-021-87989-z.
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a curative treatment for hematologic malignancies. Acute and chronic graft-versus-host disease (GvHD) are the major immune-mediated complications after alloHSCT. However, there is controversy whether neurologic complications after alloHSCT might represent manifestations of GvHD. We report three patients who acquired distinct, severe immune-mediated peripheral or central nervous system diseases after alloHSCT without other, concomitant GvHD manifestations. One patient had been diagnosed with B-cell chronic lymphocytic leukemia and two patients with high risk myelodysplastic syndrome. Patient #1 presented as LGI1- and GAD-IgG positive immune-mediated encephalitis, patient #2 was diagnosed with MOG-IgG positive encephalomyelitis, and patient #3 had chronic inflammatory polyneuropathy associated with SSA(Ro)-IgG positive Sjögren's syndrome. 100% donor chimerism was detectable in the peripheral blood in all three. The specific antibodies were undetectable in donors' and patients' blood before alloHSCT suggesting that the antibodies had arisen from the transplanted donor immune system. Early intensive immunotherapy led to improvement of clinical symptoms and stability of the neurological disease, however, at the cost of losing the graft-versus-malignancy effect in one patient. In conclusion, we provide evidence of isolated, severe allo-immune diseases of the peripheral and central nervous system as complications of alloHSCT ("neuro-GvHD"). Interdisciplinary surveillance and thorough diagnostic work-up are needed for early diagnosis and treatment of neuro-immunologic complications after alloHSCT to improve the otherwise poor outcome.
异基因造血干细胞移植(alloHSCT)是血液系统恶性肿瘤的一种根治性治疗方法。急性和慢性移植物抗宿主病(GvHD)是 alloHSCT 后的主要免疫介导的并发症。然而,对于 alloHSCT 后神经并发症是否可能代表 GvHD 的表现存在争议。我们报告了三例患者在 alloHSCT 后获得了独特的、严重的免疫介导的周围或中枢神经系统疾病,而没有其他伴随的 GvHD 表现。一名患者被诊断为 B 细胞慢性淋巴细胞白血病,两名患者为高危骨髓增生异常综合征。患者 #1 表现为 LGI1 和 GAD-IgG 阳性免疫介导性脑炎,患者 #2 被诊断为 MOG-IgG 阳性脑脊髓炎,患者 #3 患有与 SSA(Ro)-IgG 阳性干燥综合征相关的慢性炎症性多发性神经病。在所有三例患者的外周血中均检测到 100%的供者嵌合体。在 alloHSCT 之前,供者和患者的血液中均未检测到特定的抗体,这表明这些抗体是由移植的供者免疫系统产生的。早期强化免疫治疗导致临床症状改善和神经系统疾病稳定,但在一名患者中,以失去移植物抗恶性肿瘤效应为代价。总之,我们提供了证据表明,外周和中枢神经系统的孤立性、严重同种免疫疾病是 alloHSCT 的并发症(“神经 GvHD”)。需要进行跨学科监测和彻底的诊断性检查,以便早期诊断和治疗 alloHSCT 后的神经免疫并发症,从而改善预后不佳的情况。